What is BPC-157?

BPC-157 is a synthetic peptide of fifteen amino acids whose sequence corresponds to a fragment of a larger peptide first described in gastric juice. It is one of the most written-about research peptides, and the gap between its published literature and what is said about it online is unusually wide. This guide covers the reference side: origin, evidence, regulatory position, stability and how to read its certificate. For format, strength and dispatch, see the BPC-157 product page.

Reference material for laboratory research. Everything below concerns the peptide's chemistry, its published literature and its regulatory position. None of it is guidance on use in people or animals, no effect in either is claimed, and BPC-157 is sold only as a material for in-vitro work.

Identifiers and properties

The formula, masses and identifiers are PubChem reference values for the free peptide; salt forms carry separate registry numbers.

Where the sequence comes from

The compound traces to a pharmacology group at the University of Zagreb's medical faculty. The earliest PubMed record for the parent peptide dates from 1992: it refers to Body Protection Compound (BPC) as a newly, partially characterised gastric juice peptide, and does not yet name the fifteen-residue fragment (Sikiric et al., 1992). A 1993 overview from the same group described BPC as a recently isolated gastric juice peptide with a relative molecular mass of about 40,000, and reported that a fifteen-amino-acid fragment of it — BPC 157 — had been fully characterised and was thought essential to the parent molecule's activity (Sikirić et al., 1993).

The BPC-157 studied and supplied today is made by chemical synthesis, not extracted from gastric juice. It also entered pharmaceutical development early, under the development codes PL 14736, PLD-116 and PL-10, associated with the Croatian company Pliva (Sikiric et al., 2006). No authorised medicine resulted, and a 2026 appraisal of the compound's development records no approved formulation and no completed phase II trial (Mateescu et al., 2026).

The chemistry of a fifteen-residue peptide

The composition is four prolines, three glycines, two alanines, two aspartates, and one each of glutamate, lysine, leucine and valine. That short list has practical consequences for handling and analysis.

• Charge. At neutral pH the N-terminal amine and lysine carry positive charges, and the glutamate, both aspartates and the C-terminal carboxyl negative ones, giving a net charge of about −2.
• No aromatic residues. With no tryptophan, tyrosine or phenylalanine, BPC-157 absorbs almost nothing at 280 nm, so UV detection relies on the peptide bond itself at around 210–220 nm.
• Proline-rich. Four residues are proline, including a Pro-Pro-Pro run near the N-terminus. Few proteases cut next to proline (the single lysine is followed by proline, a bond trypsin does not cleave), which is consistent with, though not a full explanation for, the stability its originating group has emphasised.
• Low oxidation and deamidation risk. There is no methionine, cysteine or tryptophan, the residues most prone to oxidation, and no asparagine or glutamine to deamidate.
• Two adjacent aspartates. The Asp-Asp-Ala stretch at positions 10–12 is the most chemically sensitive part of the sequence. In water, aspartate can cyclise through a succinimide intermediate and reopen as iso-aspartate, a change that leaves the mass unchanged. The fastest-reacting aspartate motifs — Asp-Gly (isomerisation) and Asp-Pro (acid-catalysed cleavage) — are absent, but the reaction still depends on temperature and pH.

How the literature developed

The record falls into three broad phases.

1990s and 2000s: a rodent literature from one group. From 1992 the Zagreb group published a long series of studies in rats and mice, first in gastrointestinal lesion models and later in tendon, ligament, muscle and vascular models. The group continues to publish on the compound in 2026.

2010s: independent mechanistic work. Laboratories outside the originating group and its commercial partner, notably at Chang Gung University in Taiwan, published mechanistic work asking which signalling molecules change when cultured cells are exposed to the peptide (Chang et al., 2011; Chang et al., 2014; Hsieh et al., 2017).

2019 onward: appraisal and pharmacology. Outside appraisals began with a 2019 critical review from Loughborough University centred on tendon, ligament and skeletal muscle studies (Gwyer et al., 2019). A formal pharmacokinetic study in rats and dogs followed from a group in Xi'an, China (He et al., 2022), then a 2025 systematic review from an orthopaedic sports medicine perspective that identified 544 articles from 1993 to 2024 and included 36 studies, 35 of them preclinical (Vasireddi et al., 2025). A 2026 appraisal took a drug-development view (Mateescu et al., 2026).

A literature can be large and still narrow: many papers from few laboratories, in few species, measuring endpoints in models rather than in people. Reviewing the soft-tissue work, Gwyer and colleagues noted that most studies used small rodent models and that only a handful of research groups had studied the peptide in depth.

What the research actually examines

Searches for BPC-157 return long lists of claimed effects. The study types behind those lists answer different questions, and each has limits.

Three examples of mechanistic work

• Fibroblast migration and the cytoskeleton. Chang et al. (2011) used tendon explants and fibroblasts cultured from rat Achilles tendon, measuring explant outgrowth, cell survival under hydrogen-peroxide stress, transwell migration, F-actin formation and phosphorylation of focal adhesion kinase (FAK) and paxillin, and proposed the FAK–paxillin pathway as the route for the changes they recorded.
• Growth hormone receptor expression. Chang et al. (2014) examined growth hormone receptor expression in the same rat tendon fibroblast system, using cDNA microarrays followed by PCR and Western blots, together with assays of downstream JAK2 activation.
• Endothelial signalling. Hsieh et al. (2017) combined the chick chorioallantoic membrane assay, endothelial tube-formation assays and a rat hind-limb ischaemia model with experiments in cultured human vascular endothelial cells, examining VEGFR2 expression and internalisation and the VEGFR2–Akt–eNOS pathway — the nitric-oxide connection that recurs throughout this literature.

Each measures molecular or cellular endpoints in a defined system, at concentrations and exposure times the investigators chose. None establishes an effect in a person; results in this field are model- and concentration-dependent, and a finding in one system is not evidence for another.

The missing piece: controlled human data

For a compound studied for more than thirty years, the human evidence is strikingly thin.

• The 2025 systematic review, whose inclusion criteria were musculoskeletal in focus (mechanism, musculoskeletal outcomes, metabolism and safety), found one clinical study among its 36 inclusions, a retrospective report, classed the evidence as level IV and V, and found no clinical safety data (Vasireddi et al., 2025).
• The 2026 appraisal counted fewer than 30 human subjects across three uncontrolled pilot studies, none of which used a standardised pharmaceutical preparation, and described the human pharmacokinetic profile as critically under-characterised (Mateescu et al., 2026).

ClinicalTrials.gov tells the same story. A phase 1 safety and pharmacokinetic study registered in 2015 has not been updated since; randomised, masked studies registered in 2026 were recruiting or not yet open in September 2026; and no BPC-157 entry had posted results. The preclinical literature is large; a controlled human literature has not been published.

Regulatory position, in plain terms

• Not an authorised medicine. No medicines regulator has authorised BPC-157 for human use. In the UK it holds no marketing authorisation and cannot lawfully be sold or promoted as a medicine.
• United States. BPC-157 appears on the FDA's page of bulk drug substances that may present significant safety risks in compounding, among substances previously in that category whose nominations were withdrawn; the FDA's entry cites a possible risk of immunogenicity, complexities with peptide-related impurities and with characterising the active ingredient, and little or no safety information.
• Sport. The Prohibited List published by the World Anti-Doping Agency names BPC-157 in class S0, non-approved substances — pharmacological substances with no current approval from any government regulatory authority for human therapeutic use — which are prohibited at all times, in and out of competition. The list is revised every year, so check WADA's current list rather than any supplier's page, including this one.

Any BPC-157 product marketed for use in people sits outside every approval framework that exists.

Stability: in gastric juice, in animal plasma and in the vial

In gastric juice. The originating group has long emphasised the peptide's unusual stability (Sikiric et al., 2006), and the 2026 appraisal describes it as unusually stable in gastric juice (Mateescu et al., 2026).

In animal plasma. Gastric stability is a separate question from stability in the bloodstream. In rats and beagle dogs, the Xi'an study measured a short elimination half-life for the intact peptide; a tritium-labelled version showed it broken down into smaller peptide fragments and then single amino acids, excreted mainly in urine and bile (He et al., 2022).

In the vial. Here the evidence is thinnest. The 2026 appraisal found no validated pharmaceutical-grade formulation and no formal excipient-compatibility studies, and reports that no forced-degradation studies — the standard stress tests that map how a peptide breaks down — have been published for BPC-157 (Mateescu et al., 2026). From the sequence, the main chemical risks in water are slow aspartate isomerisation and backbone hydrolysis, both faster when warm, plus the risks every peptide solution shares: adsorption to surfaces, contamination once opened, and freeze–thaw damage. Hence a solution is kept sealed at 2–8 °C, never frozen, out of direct light, and used within the storage window stated for the batch. The storage guide covers handling in more detail.

Reading a certificate of analysis for BPC-157

A useful certificate for a fifteen-residue peptide lets you check its entries against the chemistry above.

1. Identity by mass spectrometry, against the right mass. The mass entry should match the expected average molecular weight of 1419.5 g/mol (monoisotopic mass 1418.70 Da). Electrospray spectra often show the singly protonated ion near m/z 1419.7 or the doubly protonated ion near m/z 710.4.
2. HPLC purity, with the method stated. Purity is the main peak's share of the total peak area. With no aromatic residues, detection belongs at around 210–220 nm, and the wavelength should be given.
3. Purity is not content. HPLC purity says how much of what was detected is BPC-157, not how much of the material is peptide. Synthetic peptides are usually isolated as salts, commonly acetate or trifluoroacetate, and hold some water, so material 99% pure by HPLC can be meaningfully less than 100% peptide by weight; peptide, water and counter-ion content are the results that account for the difference.
4. Both tests, not one. Aspartate isomerisation leaves the mass unchanged, so mass spectrometry cannot see it, while a well-resolved HPLC method may. Equally, HPLC alone cannot prove that the main peak is the right molecule.
5. Scope: which material was tested. A certificate should say what its results describe. Solution certificates often report the analytical results of the peptide batch used to fill the vials, stated as such, alongside the concentration and fill volume.
6. Batch, dates and appearance. The batch number should match the vial, the analysis should be dated, a retest or expiry date should be given, and there should be an appearance result; the liquid should be free of particles or cloudiness.

The certificate of analysis guide explains the document in general terms.

Why the pre-mixed format matters

Most BPC-157 on the market is sold as lyophilised powder, which each laboratory must dissolve before use. The volume and type of liquid added, and how completely the powder dissolves, set the concentration of the working solution, so that step and its variability are repeated at every bench.

Our BPC-157 is supplied already in solution, so dissolution happens once, before the vials are filled. The trade-off is temperature: a solution travels under cold-chain handling and is refrigerated at 2–8 °C as soon as it is received.

BPC-157 in combined preparations

BPC-157 is also a component of three multi-peptide research sets: the Wolverine Stack (BPC-157 and TB-500), the Glow Stack (BPC-157 and TB-500 with GHK-Cu) and the Klow Stack (BPC-157, TB-500, GHK-Cu and KPV). The literature described here concerns BPC-157 on its own; there is little or no published work on the combinations themselves, as the Wolverine, Glow and KLOW guides explain. For how BPC-157 differs from the thymosin beta-4 fragment, see BPC-157 vs TB-500.

What BPC-157 is not

• It is not an approved medicine in the UK or anywhere else, and it is not sold for human or veterinary use.
• It is not a natural extract. It is a synthetic peptide whose sequence was first identified in gastric juice.
• It is not supported by controlled human trials. Published human data are limited to small uncontrolled pilot studies.
• It is not permitted in competitive sport. WADA names it on the Prohibited List.
• It is not TB-500, with which it is often paired: a different molecule with a different literature, covered in the TB-500 guide and supplied as a separate vial.

Dosing and administration

We do not publish dosing, reconstitution-for-use or administration guidance for BPC-157. It is supplied only for in-vitro laboratory research and is not for human or veterinary use, so quantity guidance aimed at a person would be inconsistent with what is supplied.

How it is supplied

BPC-157 comes already dissolved, in a sealed 3 ml vial, HPLC-verified, with a batch-specific Certificate of Analysis. It is dispatched from our UK facility under cold-chain handling and stored refrigerated at 2–8 °C. The BPC-157 certificates sit in our COA library, lab-tested peptides covers the rest of the range, and strength and dispatch details are on the product page.

Related reading

• BPC-157 vs TB-500 · What is TB-500? · What is the Wolverine Stack? · What is the Glow Stack?
• What is a certificate of analysis? · What are research peptides? · Are peptides legal in the UK?